Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis

James Robert O'Dell, Kara Petersen, Robert Leff, William Palmer, Eric Schned, Kent Blakely, Claire Haire, Ana Fernandez

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective. To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA). Methods. A prospective open-label study enrolled 119 patients with RA who had active disease despite stable therapy with SSZ (n = 50), HCQ (n = 50), or intramuscular gold (n = 19). Primary efficacy endpoints consisted of American College of Rheumatology responses at 24 and 48 weeks. Safety was established at regularly scheduled visits. Results. Patients in each etanercept combination showed significant improvement at both 24 and 48 weeks. Toxicity withdrawals by 48 weeks included gold (n = 1): proteinuria; HCQ (n = 5): septic wrist and bilateral pneumonia, rash, optic neuritis, breast cancer, squamous cancer of the tongue; and SSZ (n = 5): otitis media, elevated liver function indicators, pericarditis, rash, and gastroenteritis. The most common adverse events not requiring discontinuation from the study were injection site reactions (43% of patients) and upper respiratory type infections (34%). Conclusion. This study is the first to prospectively evaluate the safety of etanercept in combination with SSZ, HCQ, and gold in patients with RA. Etanercept in combination with SSZ, HCQ, or gold was efficacious and well tolerated, with a discontinuation rate of 9% (11/119) for adverse events at 48 weeks.

Original languageEnglish (US)
Pages (from-to)213-218
Number of pages6
JournalJournal of Rheumatology
Volume33
Issue number2
StatePublished - Feb 1 2006

Fingerprint

Hydroxychloroquine
Sulfasalazine
Gold
Rheumatoid Arthritis
Exanthema
Safety
Tongue Neoplasms
Therapeutics
Optic Neuritis
Pericarditis
Gastroenteritis
Otitis Media
Wrist
Proteinuria
Respiratory Tract Infections
Pneumonia
Etanercept
Breast Neoplasms
Injections
Liver

Keywords

  • Combination therapy
  • Etanercept
  • Gold
  • Hydroxychloroquine
  • Rheumatoid arthritis
  • Sulfasalazine

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

O'Dell, J. R., Petersen, K., Leff, R., Palmer, W., Schned, E., Blakely, K., ... Fernandez, A. (2006). Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. Journal of Rheumatology, 33(2), 213-218.

Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. / O'Dell, James Robert; Petersen, Kara; Leff, Robert; Palmer, William; Schned, Eric; Blakely, Kent; Haire, Claire; Fernandez, Ana.

In: Journal of Rheumatology, Vol. 33, No. 2, 01.02.2006, p. 213-218.

Research output: Contribution to journalArticle

O'Dell, JR, Petersen, K, Leff, R, Palmer, W, Schned, E, Blakely, K, Haire, C & Fernandez, A 2006, 'Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis', Journal of Rheumatology, vol. 33, no. 2, pp. 213-218.
O'Dell, James Robert ; Petersen, Kara ; Leff, Robert ; Palmer, William ; Schned, Eric ; Blakely, Kent ; Haire, Claire ; Fernandez, Ana. / Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. In: Journal of Rheumatology. 2006 ; Vol. 33, No. 2. pp. 213-218.
@article{9848faee4a124a968e5685c6585b564f,
title = "Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis",
abstract = "Objective. To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA). Methods. A prospective open-label study enrolled 119 patients with RA who had active disease despite stable therapy with SSZ (n = 50), HCQ (n = 50), or intramuscular gold (n = 19). Primary efficacy endpoints consisted of American College of Rheumatology responses at 24 and 48 weeks. Safety was established at regularly scheduled visits. Results. Patients in each etanercept combination showed significant improvement at both 24 and 48 weeks. Toxicity withdrawals by 48 weeks included gold (n = 1): proteinuria; HCQ (n = 5): septic wrist and bilateral pneumonia, rash, optic neuritis, breast cancer, squamous cancer of the tongue; and SSZ (n = 5): otitis media, elevated liver function indicators, pericarditis, rash, and gastroenteritis. The most common adverse events not requiring discontinuation from the study were injection site reactions (43{\%} of patients) and upper respiratory type infections (34{\%}). Conclusion. This study is the first to prospectively evaluate the safety of etanercept in combination with SSZ, HCQ, and gold in patients with RA. Etanercept in combination with SSZ, HCQ, or gold was efficacious and well tolerated, with a discontinuation rate of 9{\%} (11/119) for adverse events at 48 weeks.",
keywords = "Combination therapy, Etanercept, Gold, Hydroxychloroquine, Rheumatoid arthritis, Sulfasalazine",
author = "O'Dell, {James Robert} and Kara Petersen and Robert Leff and William Palmer and Eric Schned and Kent Blakely and Claire Haire and Ana Fernandez",
year = "2006",
month = "2",
day = "1",
language = "English (US)",
volume = "33",
pages = "213--218",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "2",

}

TY - JOUR

T1 - Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis

AU - O'Dell, James Robert

AU - Petersen, Kara

AU - Leff, Robert

AU - Palmer, William

AU - Schned, Eric

AU - Blakely, Kent

AU - Haire, Claire

AU - Fernandez, Ana

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Objective. To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA). Methods. A prospective open-label study enrolled 119 patients with RA who had active disease despite stable therapy with SSZ (n = 50), HCQ (n = 50), or intramuscular gold (n = 19). Primary efficacy endpoints consisted of American College of Rheumatology responses at 24 and 48 weeks. Safety was established at regularly scheduled visits. Results. Patients in each etanercept combination showed significant improvement at both 24 and 48 weeks. Toxicity withdrawals by 48 weeks included gold (n = 1): proteinuria; HCQ (n = 5): septic wrist and bilateral pneumonia, rash, optic neuritis, breast cancer, squamous cancer of the tongue; and SSZ (n = 5): otitis media, elevated liver function indicators, pericarditis, rash, and gastroenteritis. The most common adverse events not requiring discontinuation from the study were injection site reactions (43% of patients) and upper respiratory type infections (34%). Conclusion. This study is the first to prospectively evaluate the safety of etanercept in combination with SSZ, HCQ, and gold in patients with RA. Etanercept in combination with SSZ, HCQ, or gold was efficacious and well tolerated, with a discontinuation rate of 9% (11/119) for adverse events at 48 weeks.

AB - Objective. To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA). Methods. A prospective open-label study enrolled 119 patients with RA who had active disease despite stable therapy with SSZ (n = 50), HCQ (n = 50), or intramuscular gold (n = 19). Primary efficacy endpoints consisted of American College of Rheumatology responses at 24 and 48 weeks. Safety was established at regularly scheduled visits. Results. Patients in each etanercept combination showed significant improvement at both 24 and 48 weeks. Toxicity withdrawals by 48 weeks included gold (n = 1): proteinuria; HCQ (n = 5): septic wrist and bilateral pneumonia, rash, optic neuritis, breast cancer, squamous cancer of the tongue; and SSZ (n = 5): otitis media, elevated liver function indicators, pericarditis, rash, and gastroenteritis. The most common adverse events not requiring discontinuation from the study were injection site reactions (43% of patients) and upper respiratory type infections (34%). Conclusion. This study is the first to prospectively evaluate the safety of etanercept in combination with SSZ, HCQ, and gold in patients with RA. Etanercept in combination with SSZ, HCQ, or gold was efficacious and well tolerated, with a discontinuation rate of 9% (11/119) for adverse events at 48 weeks.

KW - Combination therapy

KW - Etanercept

KW - Gold

KW - Hydroxychloroquine

KW - Rheumatoid arthritis

KW - Sulfasalazine

UR - http://www.scopus.com/inward/record.url?scp=32144453291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144453291&partnerID=8YFLogxK

M3 - Article

C2 - 16358366

AN - SCOPUS:32144453291

VL - 33

SP - 213

EP - 218

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 2

ER -